Savara (SVRA) Cash & Equivalents (2010 - 2026)

Savara (SVRA) reported Cash & Equivalents of $38.8 million for Q1 2026, up 97.96% year-over-year from $19.6 million in Q1 2025, and up 16.94% on a QoQ basis from $33.2 million in Q4 2025.

Savara (SVRA) has 17 years of Cash & Equivalents data on file, last reported at $38.8 million in Q1 2026.

  • Quarterly Cash & Equivalents rose 97.96% year-over-year to $38.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.8 million (up 97.96% YoY) and the FY2025 annual result came in at $33.2 million, up 119.33% from the prior year.
  • Cash & Equivalents improved to $38.8 million in Q1 2026 per SVRA's latest filing, from $33.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $119.8 million in Q3 2022 and bottomed at $15.1 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $26.6 million (2023), against an average of $38.8 million.
  • The widest annual swing landed in 2022, when Cash & Equivalents soared 168.1%; it then plunged 76.89% in 2023.
  • Tracing SVRA's Cash & Equivalents over 5 years: stood at $52.1 million in 2022, then tumbled by 48.97% to $26.6 million in 2023, then sank by 43.1% to $15.1 million in 2024, then soared by 119.33% to $33.2 million in 2025, then grew by 16.94% to $38.8 million in 2026.
  • Per Business Quant, the three latest SVRA Cash & Equivalents figures stand at $38.8 million (Q1 2026), $33.2 million (Q4 2025), and $16.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 1.91 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 32.30 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 286.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 61.46 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 2.77 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.49 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 18.44 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 2.96 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.71 Bn
10 Savara 1.30 Bn 1.30 Bn - 38.80 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 38.80 Mn
Dec 31, 2025 33.18 Mn
Sep 30, 2025 16.28 Mn
Jun 30, 2025 17.40 Mn
Mar 31, 2025 19.60 Mn
Dec 31, 2024 15.13 Mn
Sep 30, 2024 21.43 Mn
Jun 30, 2024 23.90 Mn
Mar 31, 2024 16.80 Mn
Dec 31, 2023 26.59 Mn
Sep 30, 2023 27.69 Mn
Jun 30, 2023 22.70 Mn
Mar 31, 2023 33.98 Mn
Dec 31, 2022 52.10 Mn
Sep 30, 2022 119.84 Mn
Jun 30, 2022 95.15 Mn
Mar 31, 2022 79.20 Mn
Dec 31, 2021 34.01 Mn
Sep 30, 2021 44.70 Mn
Jun 30, 2021 40.70 Mn
Mar 31, 2021 56.00 Mn
Dec 31, 2020 22.88 Mn
Sep 30, 2020 35.20 Mn
Jun 30, 2020 47.12 Mn
Mar 31, 2020 34.52 Mn
Dec 31, 2019 49.80 Mn
Sep 30, 2019 17.79 Mn
Jun 30, 2019 16.83 Mn
Mar 31, 2019 25.67 Mn
Dec 31, 2018 24.30 Mn
Sep 30, 2018 24.95 Mn
Jun 30, 2018 23.60 Mn
Mar 31, 2018 22.12 Mn
Dec 31, 2017 22.12 Mn
Sep 30, 2017 19.81 Mn
Jun 30, 2017 61.13 Mn
Mar 31, 2017 10.46 Mn
Dec 31, 2016 13.37 Mn
Sep 30, 2016 15.51 Mn
Jun 30, 2016 14.06 Mn
Mar 31, 2016 23.52 Mn
Dec 31, 2015 16.68 Mn
Sep 30, 2015 32.21 Mn
Jun 30, 2015 21.21 Mn
Mar 31, 2015 27.93 Mn
Dec 31, 2014 12.69 Mn
Sep 30, 2014 25.98 Mn
Jun 30, 2014 26.37 Mn
Mar 31, 2014 29.85 Mn
Dec 31, 2013 25.68 Mn
Sep 30, 2013 30.23 Mn
Jun 30, 2013 44.97 Mn
Mar 31, 2013 21.41 Mn
Dec 31, 2012 22.50 Mn
Sep 30, 2012 26.09 Mn
Jun 30, 2012 29.96 Mn
Mar 31, 2012 35.05 Mn
Dec 31, 2011 43.57 Mn
Sep 30, 2011 32.77 Mn
Jun 30, 2011 41.96 Mn
Mar 31, 2011 46.55 Mn
Dec 31, 2010 27.98 Mn
Sep 30, 2010 29.33 Mn
Jun 30, 2010 31.16 Mn